These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7197584)

  • 21. Prevalence of nephrotoxicosis associated with a short-term saline solution diuresis protocol for the administration of cisplatin to dogs with malignant tumors: 61 cases (1987-1989).
    Ogilvie GK; Straw RC; Powers BE; Cooper MF; Withrow SJ
    J Am Vet Med Assoc; 1991 Sep; 199(5):613-6. PubMed ID: 1787122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the possible role of iron and copper in cisplatin-induced nephrotoxicity in the rat.
    Goudie J; Chandra M; Lawrence GD; Williams P
    Res Commun Chem Pathol Pharmacol; 1994 Jan; 83(1):33-49. PubMed ID: 8165368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of D-methionine as a cytoprotectant in cisplatin treatment of an animal model for ovarian cancer.
    Cloven NG; Re A; McHale MT; Burger RA; DiSaia PJ; Rose GS; Campbell KC; Fan H
    Anticancer Res; 2000; 20(6B):4205-9. PubMed ID: 11205249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia.
    Zakris EL; Dewhirst MW; Riviere JE; Hoopes PJ; Page RL; Oleson JR
    J Clin Oncol; 1987 Oct; 5(10):1613-20. PubMed ID: 3655858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
    Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of fractionated low dose Cisplatin on renal functions of patients with gastric carcinoma].
    Li Y; Shen L; Li J; Jin ML
    Ai Zheng; 2007 Dec; 26(12):1354-6. PubMed ID: 18076800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole-body autoradiographic study of the distribution of 195mPt in healthy and tumor-bearing mice treated with labeled cisplatin.
    Bénard P; Desplanches G; Macquet JP; Simon J
    Cancer Treat Rep; 1983 May; 67(5):457-66. PubMed ID: 6406060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes.
    Kim WK; Kwon YE
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):237-43. PubMed ID: 17089165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner.
    Ozyurt H; Yildirim Z; Kotuk M; Yilmaz HR; Yağmurca M; Iraz M; Söğüt S; Gergerlioglu S
    J Appl Toxicol; 2004; 24(4):269-75. PubMed ID: 15300714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.
    Hirose A; Sato E; Fujii H; Sun B; Nishioka H; Aruoma OI
    Toxicol Appl Pharmacol; 2007 Jul; 222(2):152-8. PubMed ID: 17555784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy.
    Los G; Mutsaers PH; van der Vijgh WJ; Baldew GS; de Graaf PW; McVie JG
    Cancer Res; 1989 Jun; 49(12):3380-4. PubMed ID: 2720692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
    Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
    Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of cisplatin-induced nephrotoxicity by glucosides of ascorbic acid and alpha-tocopherol.
    Maliakel DM; Kagiya TV; Nair CK
    Exp Toxicol Pathol; 2008 Sep; 60(6):521-7. PubMed ID: 18644706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of cisplatin-induced nephrotoxicosis in dogs, using hypertonic saline solution as the vehicle of administration.
    Forrester SD; Fallin EA; Saunders GK; Kenny JE
    Am J Vet Res; 1993 Dec; 54(12):2175-8. PubMed ID: 8116956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacokinetics study of intraperitoneal cisplatin in ovarian carcinoma].
    Han GR; Cai GF
    Zhonghua Fu Chan Ke Za Zhi; 1993 Apr; 28(4):224-6, 254. PubMed ID: 8404307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients.
    Hu YJ; Chen Y; Zhang YQ; Zhou MZ; Song XM; Zhang BZ; Luo L; Xu PM; Zhao YN; Zhao YB; Cheng G
    Biol Trace Elem Res; 1997 Mar; 56(3):331-41. PubMed ID: 9197929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.